I'm LongbridgeAI, I can summarize articles.Galera Therapeutics plans to file Form 15 to terminate its SEC Section 12(g) registration and suspend Exchange Act reporting following its merger into Obsidian Therapeutics on August 3, 2026. Galera shares will cease quoting on the OTCQB after the merger. The deregistration becomes effective 90 days post-filing unless the SEC acts sooner.
- Galera shares expected to stop quoting on the OTCQB following completion of its merger into Obsidian Therapeutics on Aug. 3, 2026. * Form 15 filing planned after the close on Aug. 3 to terminate Section 12(g) registration, suspending Exchange Act reporting immediately. * Deregistration to become effective 90 days later unless the SEC acts sooner. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Galera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-331207), on August 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here